Residency · Residency · Medical Genetics Genomics

Spinal Muscular Atrophy: Newborn Screening and Gene Therapy Era

Introduction

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration of alpha motor neurons in the anterior horn of the spinal cord, leading to progressive muscle weakness and atrophy. With a carrier frequency of approximately 1 in 40-60 and a birth incidence of 1 in 10,000, SMA was historically the leading genetic cause of infant death. The therapeutic landscape has been transformed by newborn screening, gene therapy, and splicing modifier drugs, making SMA a paradigm of how early intervention can fundamentally alter the natural history of a genetic disease.

Molecular Genetics

The SMN Locus

SMA is caused by homozygous deletion or mutation of the SMN1 gene on chromosome 5q13. A paralog gene, SMN2, differs from SMN1 by a single nucleotide (c.840C>T) that creates an exon 7 splicing defect. As a result, SMN2 produces primarily truncated, unstable protein (delta-7 SMN), with only approximately 10% full-length functional protein. The SMN2 copy number, which ranges from 0 to 5 or more copies, is the primary genetic modifier of disease severity.

Genotype-Phenotype Correlation

Two copies of SMN2 typically correspond to SMA type 1 (severe), three copies usually produce SMA type 2 or 3, and four or more copies generally result in SMA type 3 or 4 (milder). Approximately 95% of patients have homozygous SMN1 deletion, while roughly 5% are compound heterozygotes carrying a deletion on one allele and an intragenic point mutation on the other.

Clinical Classification

SMA Type 0 (Prenatal Onset)

SMA type 0 presents with reduced fetal movements and arthrogryposis at birth. Severe respiratory failure develops rapidly, and the condition is typically fatal within weeks of life.

SMA Type 1 (Werdnig-Hoffmann Disease)

SMA type 1, the most common form historically accounting for approximately 60% of new diagnoses, has onset before 6 months of age. Affected infants never achieve the ability to sit independently. Clinical features include profound hypotonia, tongue fasciculations, areflexia, and paradoxical breathing. Without treatment, death from respiratory failure occurs by age 2.

SMA Type 2 (Intermediate)

SMA type 2 presents between 6 and 18 months of age. Children achieve sitting but never walk independently. Progressive scoliosis, joint contractures, and restrictive lung disease develop over time. With supportive care, survival into adulthood is expected.

SMA Type 3 (Kugelberg-Welander)

SMA type 3 has onset after 18 months, and affected individuals achieve independent ambulation. Proximal weakness with a positive Gower sign is characteristic, though progressive loss of ambulation may occur. A normal lifespan is expected.

SMA Type 4 (Adult Onset)

SMA type 4 presents in the second or third decade with mild proximal weakness. Patients remain ambulatory and have a normal lifespan.

Newborn Screening

Implementation

SMA was added to the Recommended Uniform Screening Panel (RUSP) in 2018 and is now screened in all 50 US states, with global expansion ongoing. The screening method uses real-time PCR on dried blood spots to detect homozygous SMN1 deletion (exon 7). Importantly, this approach does not detect point mutations or carriers, meaning approximately 5% of affected patients may be missed.

Impact of Presymptomatic Treatment

Infants treated before symptom onset demonstrate dramatically better outcomes than those treated after clinical manifestations appear. Among infants predicted to develop SMA type 1 (2 SMN2 copies), presymptomatic treatment enables the majority to achieve independent sitting and walking -- milestones that would be impossible without intervention. This underscores the critical therapeutic window, as motor neuron loss is irreversible once it occurs.

Screening Challenges

Determination of SMN2 copy number is essential following a positive screen, as it guides prognosis and treatment urgency. False negatives can occur in compound heterozygotes with point mutations. Rapid referral and treatment initiation pathways must be established to capitalize on the narrow presymptomatic window.

Diagnostic Testing

MLPA or quantitative PCR is the standard method for detecting SMN1 deletion and determining SMN2 copy number. SMN1 sequencing is performed for suspected compound heterozygotes when only one deletion is detected. Carrier testing employs quantitative analysis of SMN1 copy number, though approximately 2% of carriers have two SMN1 copies on one chromosome (the 2+0 genotype), creating false-negative carrier results. EMG and muscle biopsy were historically used but have been largely replaced by molecular diagnosis.

Therapeutic Revolution

Nusinersen (Spinraza)

Nusinersen is an antisense oligonucleotide (ASO) that modifies SMN2 pre-mRNA splicing to include exon 7, thereby increasing production of full-length functional SMN protein. It is administered intrathecally with loading doses followed by maintenance every 4 months. FDA-approved in 2016 as the first therapy for SMA, nusinersen demonstrated improved motor function and survival across all SMA types.

Onasemnogene Abeparvovec (Zolgensma)

Onasemnogene abeparvovec is an AAV9-based gene replacement therapy that delivers a functional SMN1 transgene via a single intravenous infusion. FDA-approved in 2019 for children under 2 years of age, it offers one-time treatment. Monitoring for hepatotoxicity (transaminase elevation), thrombotic microangiopathy, and immune response is required. Corticosteroid pretreatment and a structured monitoring protocol are mandatory components of administration.

Risdiplam (Evrysdi)

Risdiplam is a small molecule splicing modifier administered orally on a daily basis. FDA-approved in 2020 for patients 2 months and older, it achieves systemic distribution including CNS penetration. Its favorable safety profile and convenient oral dosing make it an attractive option for many patients.

Comparative Considerations

The three approved therapies differ in route of administration (intrathecal for nusinersen, single IV dose for onasemnogene, oral daily for risdiplam), cost (gene therapy approximately $2.1 million as a single dose, nusinersen approximately $375,000 per year, risdiplam approximately $340,000 per year), and practical considerations for patients and families. Combination therapy is under investigation but no consensus guidelines yet exist. Regardless of agent chosen, earlier treatment consistently yields better outcomes.

Multidisciplinary Management

Comprehensive SMA management requires coordination across multiple specialties. Pulmonary care includes noninvasive ventilation, cough assist devices, and airway clearance techniques. Nutritional management often involves gastrostomy tube placement for safe feeding and adequate caloric intake. Orthopedic considerations include scoliosis management and contracture prevention. Rehabilitation through physical and occupational therapy is tailored to each patient's functional level. Endocrine monitoring addresses metabolic complications including reported fatty acid oxidation defects. Psychosocial support encompasses family counseling and transition planning.

Clinical Pearls

Presymptomatic treatment is the single most important determinant of outcome in SMA, and newborn screening has been transformative in enabling early intervention before irreversible motor neuron loss. SMN2 copy number is the most important prognostic modifier, though it does not perfectly predict phenotype. Carrier testing carries an approximately 2% residual risk due to the 2+0 genotype configuration, and genetic counseling should explicitly address this limitation. The availability of three mechanistically distinct therapies creates opportunities for combination strategies while simultaneously presenting challenges for comparative effectiveness research.

References

1. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.
2. Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening. J Pediatr Neurol. 2020;18(3):145-152.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
4. Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy. Ther Clin Risk Manag. 2019;15:1153-1161.

Read this lecture as Markdown